Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems

European Journal of Pharmacology

Volumn 583, Issue 2-3, 2008, Pages 290-302

  De Bosscher, Karolien ^a   Van Craenenbroeck, Kathleen ^a   Meijer, Onno C ^b   Haegeman, Guy ^a  

^a GHENT UNIVERSITY   (Belgium)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Glucocorticoid receptor; HPA; Inflammation; NF B; Stress; Transrepression

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; AL 438; ALDOSTERONE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HEAT SHOCK PROTEIN 90; HISTONE ACETYLTRANSFERASE; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; LEUCINE ZIPPER PROTEIN; MIFEPRISTONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR 2; PREDNISOLONE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SEROTONIN RECEPTOR; STEROID 11BETA MONOOXYGENASE; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BIPOLAR DISORDER; CORTICOSTEROID THERAPY; DRUG DNA BINDING; GENE REPRESSION; HOMEOSTASIS; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; MENTAL DISEASE; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRESS; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; BRAIN DISEASES; GLUCOCORTICOIDS; HUMANS; IMMUNE SYSTEM DISEASES; MINERALOCORTICOIDS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC;

EID: 40849117947     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.076     Document Type: Review

References (156)

1. Adams M., Meijer O.C., Wang J., Bhargava A., and Pearce D. Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol. Endocrinol. 17 (2003) 2583-2592
2. Adcock I.M., Caramori G., and Ito K. New insights into the molecular mechanisms of corticosteroids actions. Curr. Drug Targets 7 (2006) 649-660
3. Adom J., Carr K.D., Gouilleux F., Marsaud V., and Richard-Foy H. Chromatin structure of hormono-dependent promoters. J. Steroid Biochem. Mol. Biol. 40 (1991) 325-332
4. Akritopoulou-Zanze I., Patel J.R., Hartandi K., Brenneman J., Winn M., Pratt J.K., Grynfarb M., Goos-Nisson A., Von Geldern T.W., and Kym P.R. Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 14 (2004) 2079-2082
5. Arana G.W., Santos A.B., Laraia M.T., McLeod-Bryant S., Beale M.D., Rames L.J., Roberts J.M., Dias J.K., and Molloy M. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am. J. Psychiatry 152 (1995) 265-267
6. Barnes P.J. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol. Allergy Clin. North Am. 25 (2005) 451-468
7. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
8. Beato M. Transcriptional control by nuclear receptors. FASEB J. 5 (1991) 2044-2051
9. Beischlag T.V., Marchese A., Meador-Woodruff J.H., Damask S.P., O'Dowd B.F., Tyndale R.F., van Tol H.H., Seeman P., and Niznik H.B. The human dopamine D5 receptor gene: cloning and characterization of the 5′-flanking and promoter region. Biochemistry 34 (1995) 5960-5970
10. Belanoff J.K., Flores B.H., Kalezhan M., Sund B., and Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21 (2001) 516-521
11. Belvisi M.G., Brown T.J., Wicks S., and Foster M.L. New glucocorticosteroids with an improved therapeutic ratio?. Pulm. Pharmacol. Ther. 14 (2001) 221-227
12. Belvisi M.G., Wicks S.L., Battram C.H., Bottoms S.E., Redford J.E., Woodman P., Brown T.J., Webber S.E., and Foster M.L. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. 166 (2001) 1975-1982
13. Bhalla V., Soundararajan R., Pao A.C., Li H., and Pearce D. Disinhibitory pathways for control of sodium transport: regulation of ENaC by SGK1 and GILZ. Am. J. Physiol., Renal Fluid Electrolyte Physiol. 291 (2006) F714-F721
14. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Kunzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Kohnlein O., Dabitz H., Bruckl T., Muller N., Pfister H., Lieb R., Mueller J.C., Lohmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., and Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004) 1319-1325
15. Bousios S., Karandrea D., Kittas C., and Kitraki E. Effects of gender and stress on the regulation of steroid receptor coactivator-1 expression in the rat brain and pituitary. J. Steroid Biochem. Mol. Biol. 78 (2001) 401-407
16. Brouwer J.P., Appelhof B.C., van Rossum E.F., Koper J.W., Fliers E., Huyser J., Schene A.H., Tijssen J.G., Van Dyck R., Lamberts S.W., Wiersinga W.M., and Hoogendijk W.J. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 31 (2006) 1154-1163
17. Buttgereit F., Burmester G.R., and Lipworth B.J. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365 (2005) 801-803
18. Caldenhoven E., Lidén J., Wissink S., Van de Stolpe A., Raaijmakers J., Koenderman L., Okret S., Gustafsson J.A., and Van der Saag P.T. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9 (1995) 401-412
19. Cannarile L., Zollo O., D'Adamio F., Ayroldi E., Marchetti C., Tabilio A., Bruscoli S., and Riccardi C. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene. Cell Death Differ. 8 (2001) 201-203
20. Chang T.J., Scher B.M., Waxman S., and Scher W. Inhibition of mouse GATA-1 function by the glucocorticoid receptor: possible mechanism of steroid inhibition of erythroleukemia cell differentiation. Mol. Endocrinol. 7 (1993) 528-542
21. Chikanza I.C. Mechanisms of corticosteroid resistance in rheumatoid arthritis: a putative role for the corticosteroid receptor beta isoform. Ann. N. Y. Acad. Sci. 966 (2002) 39-48
22. Chrousos G.P., and Gold P.W. A healthy body in a healthy mind-and vice versa-the damaging power of "uncontrollable" stress. J. Clin. Endocrinol. Metab. 83 (1998) 1842-1845
23. Chrousos G.P., and Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10 (2007) 213-219
24. Chu J.W., Matthias D.F., Belanoff J., Schatzberg A., Hoffman A.R., and Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. 86 (2001) 3568-3573
25. Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 275 (2007) 79-97
26. Coghlan M.J., Jacobson P.B., Lane B., Nakane M., Lin C.W., Elmore S.W., Kym P.R., Luly J.R., Carter G.W., Turner R., Tyree C.M., Hu J., Elgort M., Rosen J., and Miner J.N. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 17 (2003) 860-869
27. Datson N.A., van der Perk J., de Kloet E.R., and Vreugdenhil E. Identification of corticosteroid-responsive genes in rat hippocampus using serial analysis of gene expression. Eur. J. Neurosci. 14 (2001) 675-689
28. DeBattista C., Belanoff J., Glass S., Khan A., Horne R.L., Blasey C., Carpenter L.L., and Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 60 (2006) 1343-1349
29. De Bosscher K., Vanden Berghe W., and Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109 (2000) 16-22
30. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 (2003) 488-522
31. De Bosscher K., Vanden Berghe W., Beck I.M., Van Molle W., Hennuyer N., Hapgood J., Libert C., Staels B., Louw A., and Haegeman G. A fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15827-15832
32. De Bosscher K., Vanden Berghe W., and Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 25 (2006) 6868-6886
33. de Kloet E.R. Hormones and the stressed brain. Ann. N. Y. Acad. Sci. 1018 (2004) 1-15
34. de Kloet E.R., Oitzl M.S., and Joels M. Stress and cognition: are corticosteroids good or bad guys?. Trends Neurosci. 22 (1999) 422-426
35. de Kloet E.R., Derijk R.H., and Meijer O.C. Therapy insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 168-179
36. DeRijk R., and de Kloet E.R. Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine 28 (2005) 263-270
37. Dewint P., Gossye V., De Bosscher K., Vanden Berghe W., Deforce D., Van Calenbergh S., Müller-Ladner U., Vander Cruyssen B., Verbruggen G., Haegeman G., and Elewaut D. A plant-derived ligand favouring monomeric glucocorticoid receptor confirmation with impaired transactivation potential attenuates collagen-induced arthritis. J. Immunol. 180 4 (2008) 2608-2615
38. Diamond M.I., Miner J.N., Yoshinaga S.K., and Yamamoto K.R. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249 (1990) 1266-1272
39. Dijsselbloem N., Goriely S., Albarani V., Gerlo S., Francoz S., Marine J.C., Goldman M., Haegeman G., and Vanden Berghe W. A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to genistein. J. Immunol. 178 (2007) 5048-5057
40. Drouin J., Maira M., and Philips A. Novel mechanism of action for Nur77 and antagonism by glucocorticoids: a convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription. J. Steroid Biochem. Mol. Biol. 65 (1998) 59-63
41. Duprez D.A. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J. Clin. Hypertens. (Greenwich) 9 (2007) 13-18
42. Einstein M., Greenlee M., Rouen G., Sitlani A., Santoro J., Wang C., Pandit S., Mazur P., Smalera I., Weaver A.P., Zeng Y.Y., Ge L., Kelly T., Paiva T., Geissler W., Mosley R.T., Williamson J., Ali A., Balkovec J., and Harris G. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. J. Steroid Biochem. Mol. Biol. 92 (2004) 345-356
43. Evans R.M. Molecular characterization of the glucocorticoid receptor. Recent Prog. Horm. Res. 45 (1989) 1-22
44. Fiebeler A., Muller D.N., Shagdarsuren E., and Luft F.C. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 16 (2007) 134-142
45. Flores B.H., Kenna H., Keller J., Solvason H.B., and Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31 (2006) 628-636
46. Funder J.W. Glucocorticoid receptors. J. Steroid Biochem. Mol. Biol. 43 (1992) 389-394
47. Funder J.W. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am. J. Cardiovasc. Drugs 7 (2007) 151-157
48. Funder J.W., Pearce P.T., Smith R., and Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 (1988) 583-585
49. Gilmore T.D., and Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25 (2006) 6887-6899
50. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev., Immunol. 6 (2006) 44-55
51. Gold P.W., Licinio J., Wong M.L., and Chrousos G.P. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann. N. Y. Acad. Sci. 771 (1995) 716-729
52. Gómez-Sánchez E.P. Central hypertensive effects of aldosterone. Front. Neuroendocrinol. 18 (1997) 440-462
53. Hammond G.L., Smith C.L., Paterson N.A., and Sibbald W.J. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J. Clin. Endocrinol. Metab. 71 (1990) 34-39
54. Hasselgren P.O. Glucocorticoids and muscle catabolism. Curr. Opin. Clin. Nutr. Metab. Care 2 (1999) 201-205
55. Heck S., Kullmann M., Gast A., Ponta H., Rahmsdorf H.J., Herrlich P., and Cato A.C. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13 (1994) 4087-4095
56. Holmes M.C., and Seckl J.R. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol. Cell. Endocrinol. 248 (2006) 9-14
57. Imai E., Miner J.N., Mitchell J.A., Yamamoto K.R., and Granner D.K. Glucocorticoid receptor-cAMP response element-binding protein interaction and the response of the phosphoenolpyruvate carboxykinase gene to glucocorticoids. J. Biol. Chem. 268 (1993) 5353-5356
58. Ito K., Getting S.J., and Charron C.E. Mode of glucocorticoid actions in airway disease. Sci. World J. 6 (2006) 1750-1769
59. Ito K., Yamamura S., Essilfie-Quaye S., Cosio B., Ito M., Barnes P.J., and Adcock I.M. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203 (2006) 7-13
60. Jiang W., Fiordeliso J.J., Allan G., Linton O., Tannenbaum P., Xu J., Zhu P., Gunnet J., Demarest K., Lundeen S., and Sui Z. Discovery of novel phosphorus-containing steroids as selective glucocorticoid receptor antagonist. Bioorg. Med. Chem. Lett. 17 (2007) 1471-1474
61. Joëls M. Steroid hormones and excitability in the mammalian brain. Front. Neuroendocrinol. 18 (1997) 2-48
62. Joëls M., and Van Riel E. Mineralocorticoid and glucocorticoid receptor-mediated effects on serotonergic transmission in health and disease. Ann. N. Y. Acad. Sci. 1032 (2004) 301-303
63. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C., Gebel S., Ponta H., and Herrlich P. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62 (1990) 1189-1204
64. Kaltschmidt B., Widera D., and Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim. Biophys. Acta 1745 (2005) 287-299
65. Karssen A.M., Meijer O.C., van der Sandt I.C., Lucassen P.J., de Lange E.C., de Boer A.G., and de Kloet E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142 (2001) 2686-2694
66. Karssen A.M., Meijer O.C., van der Sandt I.C., De Boer A.G., De Lange E.C., and de Kloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 175 (2002) 251-260
67. Karssen A.M., Meijer O.C., Berry A., Sanjuan Pinol R., and de Kloet E.R. Low doses of dexamethasone can produce a hypocorticosteroid state in the brain. Endocrinology 146 (2005) 5587-5595
68. Karst H., Karten Y.J., Reichardt H.M., de Kloet E.R., Schütz G., and Joëls M. Corticosteroid actions in hippocampus require DNA binding of glucocorticoid receptor homodimers. Nat. Neurosci. 3 (2000) 977-978
69. Karst H., Berger S., Turiault M., Tronche F., Schütz G., and Joëls M. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19204-19207
70. Kellendonk C., Gass P., Kretz O., Schutz G., and Tronche F. Corticosteroid receptors in the brain: gene targeting studies. Brain Res. Bull. 57 (2002) 73-83
71. Krugers H.J., Goltstein P.M., van der Linden S., and Joëls M. Blockade of glucocorticoid receptors rapidly restores hippocampal CA1 synaptic plasticity after exposure to chronic stress. Eur. J. Neurosci. 23 (2006) 3051-3055
72. Lee J.C., Kundu J.K., Hwang D.M., Na H.K., and Surh Y.J. Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-kappaB and AP-1: IkappaB kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis 28 (2007) 1491-1498
73. Liberman A.C., Druker J., Perone M.J., and Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 18 (2007) 45-56
74. Liberman A.C., Refojo D., Druker J., Toscano M., Rein T., Holsboer F., and Arzt E. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. 21 (2007) 1177-1188
75. Lidén J., Delaunay F., Rafter I., Gustafsson J., and Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 272 (1997) 21467-21472
76. Lidén J., Rafter I., Truss M., Gustafsson J.A., and Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem. Biophys. Res. Commun. 273 (2000) 1008-1014
77. Liu D., Diorio J., Tannenbaum B., Caldji C., Francis D., Freedman A., Sharma S., Pearson D., Plotsky P.M., and Meaney M.J. Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 277 (1997) 1659-1662
78. Lonard D.M., and O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125 (2006) 411-414
79. Louw A., and Swart P. Salsola tuberculatiformis Botschantzev and an aziridine precursor analog mediate the in vivo increase in free corticosterone and decrease in corticosteroid-binding globulin in female Wistar rats. Endocrinology 140 (1999) 2044-2053
80. Lowy M.T. Corticosterone regulation of brain and lymphoid corticosteroid receptors. J. Steroid Biochem. Mol. Biol. 39 (1991) 147-154
81. Lu N.Z., and Cidlowski J.A. Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell Biol. 16 (2006) 301-307
82. Lupien S.J., de Leon M., de Santi S., Convit A., Tarshish C., Nair N.P., Thakur M., McEwen B.S., Hauger R.L., and Meaney M.J. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat. Neurosci. 1 (1998) 69-73
83. Malkoski S.P., and Dorin R.I. Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene. Mol. Endocrinol. 13 (1999) 1629-1644
84. Mayer J.L., Klumpers L., Maslam S., de Kloet E.R., Joëls M., and Lucassen P.J. Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. J. Neuroendocrinol. 18 (2006) 629-631
85. McEwen B.S., and Sapolsky R.M. Stress and cognitive function. Curr. Opin. Neurobiol. 5 (1995) 205-216
86. Meffert M.K., and Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci. 28 (2005) 37-43
87. Meijer O.C. Understanding stress through the genome. Stress 9 (2006) 61-67
88. Meijer O.C., and de Kloet E.R. A role for the mineralocorticoid receptor in a rapid and transient suppression of hippocampal 5-HT1A receptor mRNA by corticosterone. J. Neuroendocrinol. 7 (1995) 653-657
89. Meijer O.C., and de Kloet E.R. Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity. Crit. Rev. Neurobiol. 12 (1998) 1-20
90. Meijer O.C., Steenbergen P.J., and de Kloet E.R. Differential expression and regional distribution of steroid receptor coactivators SRC-1 and SRC-2 in brain and pituitary. Endocrinology 141 (2000) 2192-2199
91. Meijer O.C., Williamson A., Dallman M.F., and Pearce D. Transcriptional repression of the 5-HT1A receptor promoter by corticosterone via mineralocorticoid receptors depends on the cellular context. J. Neuroendocrinol. 12 (2000) 245-254
92. Meijer O.C., Karssen A.M., and de Kloet E.R. Cell- and tissue-specific effects of corticosteroids in relation to glucocorticoid resistance: examples from the brain. J. Endocrinol. 178 (2003) 13-18
93. Meijer O.C., Kalkhoven E., van der Laan S., Steenbergen P.J., Houtman S.H., Dijkmans T.F., Pearce D., and de Kloet E.R. Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology 146 (2005) 1438-1448
94. Metselaar J.M., van den Berg W.B., Holthuysen A.E., Wauben M.H., Storm G., and van Lent P.L. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis. 63 (2004) 348-353
95. Miner J.N., Hong M.H., and Negro-Vilar A. New and improved glucocorticoid receptor ligands. Expert Opin. Investig. Drugs 14 (2005) 1527-1545
96. Misiti S., Schomburg L., Yen P.M., and Chin W.W. Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 139 (1998) 2493-2500
97. Mizoguchi K., Ishige A., Takeda S., Aburada M., and Tabira T. Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J. Neurosci. 24 (2004) 5492-5499
98. Morgan B.P., Swick A.G., Hargrove D.M., LaFlamme J.A., Moynihan M.S., Carroll R.S., Martin K.A., Lee E., Decosta D., and Bordner J. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J. Med. Chem. 45 (2002) 2417-2424
99. Morsink M.C., Steenbergen P.J., Vos J.B., Karst H., Joëls M., de Kloet E.R., and Datson N.A. Acute activation of hippocampal glucocorticoid receptors results in different waves of gene expression throughout time. J. Neuroendocrinol. 18 (2006) 239-252
100. Morsink M.C., Van Gemert N.G., Steenbergen P.J., Joëls M., de Kloet E.R., and Datson N.A. Rapid glucocorticoid effects on the expression of hippocampal neurotransmission-related genes. Brain Res. 1150 (2007) 14-20
101. Necela B.M., and Cidlowski J.A. Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc. Am. Thorac. Soc. 1 (2004) 239-246
102. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721
103. Oitzl M.S., Reichardt H.M., Joëls M., and de Kloet E.R. Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12790-12795
104. O'Malley B.W. Coregulators: from whence came these "master genes". Mol. Endocrinol. 21 (2007) 1009-1013
105. Pariante C.M., Kim R.B., Makoff A., and Kerwin R.W. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br. J. Pharmacol. 139 (2003) 1111-1118
106. Pascual G., and Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17 (2006) 321-327
107. Paul-Clark M.J., Mancini L., Del Soldato P., Flower R.J., and Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1677-1682
108. Paul-Clark M.J., Roviezzo F., Flower R.J., Cirino G., Soldato P.D., Adcock I.M., and Perretti M. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J. Immunol. 171 (2003) 3245-3252
109. Pearce D., and Yamamoto K.R. Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. Science 259 (1993) 1161-1165
110. Peeters B.W., Tonnaer J.A., Groen M.B., Broekkamp C.L., van der Voort H.A., Schoonen W.G., Smets R.J., Vanderheyden P.M., Gebhard R., and Ruigt G.S. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress 7 (2004) 233-241
111. Qiu Y., Zhao Y., Becker M., John S., Parekh B.S., Huang S., Hendarwanto A., Martinez E.D., Chen Y., Lu H., Adkins N.L., Stavreva D.A., Wiench M., Georgel P.T., Schiltz R.L., and Hager G.L. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol. Cell 22 (2006) 669-679
112. Reichardt H.M., and Schütz G. Glucocorticoid signalling-multiple variations of a common theme. Mol. Cell. Endocrinol. 146 (1998) 1-6
113. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., and Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93 (1998) 531-541
114. Reichardt H.M., Tuckermann J.P., Bauer A., and Schütz G. Molecular genetic dissection of glucocorticoid receptor function in vivo. Z. Rheumatol. 59 Suppl. 2 (2000) II/1-II/5
115. Reichardt H.M., Tuckermann J.P., Göttlicher M., Vujic M., Weih F., Angel P., Herrlich P., and Schütz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20 (2001) 7168-7173
116. Reul J.M., Stec I., Wiegers G.J., Labeur M.S., Linthorst A.C., Arzt E., and Holsboer F. Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J. Clin. Invest. 93 (1994) 2600-2607
117. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353 (2005) 1711-1723
118. Robson A.C., Leckie C.M., Seckl J.R., and Holmes M.C. 11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Res. Mol. Brain Res. 61 (1998) 1-10
119. Rogatsky I., and Ivashkiv L.B. Glucocorticoid modulation of cytokine signaling. Tissue Antigens 68 (2006) 1-12
120. Rogatsky I., Zarember K.A., and Yamamoto K.R. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20 (2001) 6071-6083
121. Rogatsky I., Luecke H.F., Leitman D.C., and Yamamoto K.R. Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16701-16706
122. Rogatsky I., Wang J.C., Derynck M.K., Nonaka D.F., Khodabakhsh D.B., Haqq C.M., Darimont B.D., Garabedian M.J., and Yamamoto K.R. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13845-13850
123. Rosen J., and Miner J.N. The search for safer glucocorticoid receptor ligands. Endocr. Rev. 26 (2005) 452-464
124. Sabban E.L., and Kvetnansky R. Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events. Trends Neurosci. 24 (2001) 91-98
125. Sabban E.L., Hebert M.A., Liu X., Nankova B., and Serova L. Differential effects of stress on gene transcription factors in catecholaminergic systems. Ann. N. Y. Acad. Sci. 1032 (2004) 130-140
126. Sabban E.L., Nankova B.B., Serova L.I., Kvetnansky R., and Liu X. Molecular regulation of gene expression of catecholamine biosynthetic enzymes by stress: sympathetic ganglia versus adrenal medulla. Ann. N. Y. Acad. Sci. 1018 (2004) 370-377
127. Schaaf M.J., and Cidlowski J.A. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 83 (2002) 37-48
128. Schäcke H., Docke W.D., and Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96 (2002) 23-43
129. Schäcke H., Schottelius A., Docke W.D., Strehlke P., Jaroch S., Schmees N., Rehwinkel H., Hennekes H., and Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 227-232
130. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., and Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
131. Schmidt J., Metselaar J.M., Wauben M.H., Toyka K.V., Storm G., and Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126 (2003) 1895-1904
132. Schüle R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., and Evans R.M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62 (1990) 1217-1226
133. Stöcklin E., Wissler M., Moriggl R., and Groner B. Specific DNA binding of Stat5, but not of glucocorticoid receptor, is required for their functional cooperation in the regulation of gene transcription. Mol. Cell. Biol. 17 (1997) 6708-6716
134. Trapp T., and Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trends Pharmacol. Sci. 17 (1996) 145-149
135. Tronche F., Kellendonk C., Reichardt H.M., and Schütz G. Genetic dissection of glucocorticoid receptor function in mice. Curr. Opin. Genet. Dev. 8 (1998) 532-538
136. Tronche F., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., Bock R., Klein R., and Schütz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 23 (1999) 99-103
137. Tronche F., Opherk C., Moriggl R., Kellendonk C., Reimann A., Schwake L., Reichardt H.M., Stangl K., Gau D., Hoeflich A., Beug H., Schmid W., and Schütz G. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev. 18 (2004) 492-497
138. Turner-Cobb J.M. Psychological and stress hormone correlates in early life: a key to HPA-axis dysregulation and normalisation. Stress 8 (2005) 47-57
139. Ulmann A., Teutsch G., and Philibert D. Ru 486. Sci. Am. 262 (1990) 42-48
140. Unlap M.T., and Jope R.S. Dexamethasone attenuates NF-kappa B DNA binding activity without inducing I kappa B levels in rat brain in vivo. Brain Res. Mol. Brain Res. 45 (1997) 83-89
141. Urani A., and Gass P. Corticosteroid receptor transgenic mice: models for depression?. Ann. N. Y. Acad. Sci. 1007 (2003) 379-393
142. Van Craenenbroeck K., De Bosscher K., Vanden Berghe W., Vanhoenacker P., and Haegeman G. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Mol. Cell. Endocrinol. 245 (2005) 10-22
143. van den Akker E.L., Russcher H., van Rossum E.F., Brinkmann A.O., de Jong F.H., Hokken A., Pols H.A., Koper J.W., and Lamberts S.W. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J. Clin. Endocrinol. Metab. 91 (2006) 2800-2803
144. Vanden Berghe W., Francesconi E., De Bosscher K., Resche-Rigon M., and Haegeman G. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Mol. Pharmacol. 56 (1999) 797-806
145. van der Lely A.J., Foeken K., van der Mast R.C., and Lamberts S.W. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann. Intern. Med. 114 (1991) 143-144
146. van de Werve G., Lange A., Newgard C., Mechin M.C., Li Y., and Berteloot A. New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system. Eur. J. Biochem. 267 (2000) 1533-1549
147. van Rossum E.F., Binder E.B., Majer M., Koper J.W., Ising M., Modell S., Salyakina D., Lamberts S.W., and Holsboer F. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59 (2006) 681-688
148. van West D., Van Den Eede F., Del-Favero J., Souery D., Norrback K.F., Van Duijn C., Sluijs S., Adolfsson R., Mendlewicz J., Deboutte D., Van Broeckhoven C., and Claes S. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 31 (2006) 620-627
149. Vayssière B.M., Dupont S., Choquart A., Petit F., Garcia T., Marchandeau C., Gronemeyer H., and Rèsche-Rigon M. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11 (1997) 1245-1255
150. Wang J.C., Shah N., Pantoja C., Meijsing S.H., Ho J.D., Scanlan T.S., and Yamamoto K.R. Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev. 20 (2006) 689-699
151. Wei Q., Lu X.Y., Liu L., Schafer G., Shieh K.R., Burke S., Robinson T.E., Watson S.J., Seasholtz A.F., and Akil H. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11851-11856
152. Wust S., Van Rossum E.F., Federenko I.S., Koper J.W., Kumsta R., and Hellhammer D.H. Common polymorphisms in the glucocorticoid receptor gene are associated with adrenocortical responses to psychosocial stress. J. Clin. Endocrinol. Metab. 89 (2004) 565-573
153. Yang-Yen H.F., Chambard J.C., Sun Y.L., Smeal T., Schmidt T.J., Drouin J., and Karin M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62 (1990) 1205-1215
154. Young A.H. Antiglucocorticoid treatments for depression. Aust. N. Z. J. Psychiatry 40 (2006) 402-405
155. Young A.H., Gallagher P., Watson S., Del-Estal D., Owen B.M., and Ferrier I.N. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29 (2004) 1538-1545
156. Yudt M.R., and Cidlowski J.A. The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol. Endocrinol. 16 (2002) 1719-1726